Navigation Links
Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
Date:6/10/2008

ential for intervals of administration without the use of a matrix. Taspoglutide is currently moving into Phase III clinical trials.

About Diabetes

Diabetes is a disease characterized by excess blood glucose due to a deficiency in insulin availability and/or resistance to its action. Type 2 diabetes accounts for 90% to 95% of all diabetes cases worldwide and occurs almost entirely in adults. Complications from diabetes, such as coronary artery and peripheral vascular disease, stroke, diabetic neuropathy, amputations, renal failure and blindness, are resulting in increasing disability, reduced life expectancy and enormous health cost for virtually every society. According to current estimates by the World Health Organization, the number of people with diabetes is set to more than double in the next 20 years to over 300 million by the year 2025.

About Roche

Hoffmann-La Roche Inc. (Roche), in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, a leading, global healthcare company. For more than 100 years, Roche has been developing innovative products and services that address prevention, diagnosis and treatment of disease. For more information, visit http://www.rocheusa.com. Product and treatment information for U.S. healthcare professionals is available at http://www.RocheExchange.com.

About Ipsen

Ipsen is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000. Its development strategy is based on a combination of specialty products, which are growth drivers, in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, L
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
2. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
3. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
4. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
5. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Roche responds to announcement of IDEAL hepatitis C trial results
8. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
9. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
10. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
11. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...,Texas,Nov.23/PRNewswire-FirstCall/-- LexiconPharm...top-linedatafromitsPhase2clinicalstudywith LX1031 ...me(IBS)willbepresentedatGASTRO2009inLondonthisweek...ementinIBSsymptoms,willbepresentedbyDr. PhilipM.Br...ment,onNovember25,2009at2:30pmlocaltimeatthesessio...
(Date:11/23/2009)...xas,Nov.23/PRNewswire-FirstCall/--WoundManagementT...owingproviderofspecialtymedicalproducts,announcedt...dacomprehensivemanagementbusinessupdatetoillustrat...Q32009salesincreased33.5%to$102,926vs.Q32008saleso...reasedto$3,327,892vs.Q32008shareholderequityof$(32...
(Date:11/23/2009)...CISCO,Calif.,Nov.23/PRNewswire-FirstCall/--Anesiva...andDr.DavidC.U,PrichardhaveagreedtojointheAnesivab...gerbetweenAnesivaandArcionTherapeutics.Completiono...keplaceatthepreviouslyannouncedAnesiva2009AnnualMe...a.m.PSTat400OysterPoint,Suite107A,SouthSanFrancisc...
Breaking Medicine Technology:Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 2Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 1FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 2FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 3FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 4FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 5FDA Approves Lamictal 28R 29XR 28TM 29 3B An Extended Release Once Daily New Generation Treatment for Epilepsy 47447 6For Patients With Irritable Bowel Syndrome 28IBS 29 iPhone to the Rescue 47442 1For Patients With Irritable Bowel Syndrome 28IBS 29 iPhone to the Rescue 47442 2For Patients With Irritable Bowel Syndrome 28IBS 29 iPhone to the Rescue 47442 3NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 1NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 2NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 3NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 4NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 5NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 6NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 7NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD 26 NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 12377 8
...an Biosciences,Incorporated (Nasdaq: KOSN ) today...tanespimycin, the company,s lead Hsp90 inhibitor, ...(R) in patients with HER2-positive,metastatic brea...can,Society of Clinical Oncology (ASCO), being hel...une 3, 2008., Abstract 1027, titled, "Phase 2 tri...
... Review Data Tuesday, May 13 at 1:00 p.m. EDT ...A, Spain and MENLO PARK, Calif., May 13 /PRNewswir... announced positive six-month follow-up,data from ...safety and,efficacy of the Custom NX(R) drug eluti...s with coronary artery disease., The CUSTOM III c...
Other Medicine Technology:Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 2Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 3XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 2XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 3XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 4
(Date:11/23/2009)...tes Department of Agriculture (USDA) has awarded a... University of Minnesota to complete sequencing th...lopavo. The funding will be used by the Turkey Gen...equencing using next-generation sequencing platfor...es and functions in the final genome sequence by u...
(Date:11/23/2009)...-FirstCall/--AnnTaylorStoresCorp.announcedtodaytha...lThanksandGivingcampaign,aholidayfundraisingandawa...ThisyearmarksthethirdyearthatAnnTaylor,throughitsA...nthecampaignwhereweofferourshoppersanopportunityto...ppingthisholidayseason.ClientswhoshopatAnnTaylor,L...
(Date:11/23/2009)...ire/--Thanksgivingweekendmarksthe36thannualStateFa...icrepresentsthesportsmanshipandprideoftwoschoolsbu...hoseinattendance. ,, ForthecrewofthenewU.S.Coas...mebeforetheyworktotestandlaunchabrandnewshiptoprot...ttyOfficerClaudeBovellandtherestofthecrewwillbegin...
(Date:11/23/2009)...ally modified to produce bacterial proteins that a...have been planted on more than 200 million hectare...ed after the bacterium Bacillus thuringiensis , c...allowing farmers to save money and lessen environm...However, since insects can evolve resistance to to...
(Date:11/23/2009)...ger to get sick, study finds , , MONDAY,...t a genetic variation appears to play a major role...tients. , In fact, those with the variation a... of complications of the disease. , "We,re ho...at make a person more or less susceptible to HIV, ...
Breaking Medicine News(10 mins):Health News:Turkey Genome Sequencing Consortium awarded $0.9 million from USDA 2Health News:Ann Taylor Stores Corp. Returns To St. Jude Children's Research Hospital's Thanks and Giving Campaign(R) For The Third Year 2Health News:Nothing Is Like Being There 2Health News:Insect resistance to Bt crops can be predicted, monitored and managed 2Health News:Genetic Variant Slows AIDS Progression 2
... Leading Researchers to Discuss, State of Breast ... Cures, BOSTON, April 9 The Massachusetts Affili...posium April 10 at Harvard Medical,School, featuri...d the need for more funding to ensure that critica...
...s becoming popular, survey finds , , WEDNE...ondents to a new survey acknowledges using so-call... heart medications -- to stimulate their focus, co...ut has emerged in recent years as a campus "study ...
...Care and Frida,Kahlo Store are proud to announce t...8 for the benefit of The Leukemia & Lymphoma Socie...sance, located at 2131 Hylan,Boulevard, Staten Isl... problems., The event will consist of a dinner-co...
...ia,Academy of Family Physicians Foundation (PAFP/F...amily medicine student scholarship programs., "Th...dle the continuing,demand for primary care," said ...we have to make sure they get every,opportunity to...
...n the United,States has doubled in the last 30 yea...tom lines, according to a new report from The Conf... fit the definition of "obese.",Obese employees co...yers Should Know about,Obesity, The Conference Boa...
...ingerprint associated with normal embryonic stem c...tion of cancer stem cells. The research, published...m Cell, demonstrates that embryonic stem cells and...nificant clinical implications for cancer therapeu...
Other Medicine News:Health News:Massachusetts Affiliate of Susan G. Komen for the Cure to Spotlight Gaps in Breast Cancer Research 2Health News:Unlikely Drugs Emerge as 'Cognition Enhancers' 2Health News:PAFP Golf Tournament to Benefit Student Programs 2Health News:Obesity Costs U.S. Companies as Much as $45 Billion a Year, The Conference Board Reports 2Health News:Obesity Costs U.S. Companies as Much as $45 Billion a Year, The Conference Board Reports 3Health News:Module map links embryonic stem cells and cancer stem cells 2
...6 mm tip is angled 90 degrees with 1 mm flattened ...ure extension tube (0.03 inch ID x 8 inch long), f...r dissecting pre-retinal and other vitreo-retinal ..., angled tip of 30 gauge cannula facilitates place...
Vitreoretinal Micro Cannula
Moist Air Humidifying Chambers
Eye Garter Shield Cover - white
Medicine Products: